Gemcitabine resistance in pancreatic ductal adenocarcinoma- 学术资源搜索

过去一年中添加的文章，按日期排序

Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1

C Yu, Y Su, X Miao, C Chai, H Tang, L Li, J Yi, Z Ye… - BMC cancer, 2024 - Springer

3 天前 - Drug resistance remains a significant challenge in the treatment of pancreatic
cancer. The development of drug-resistant cell lines is crucial to understanding the underlying …

Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma.

A Shah, R Jahan, SG Kisling, P Atri, G Natarajan… - Cancer Letters, 2024 - Elsevier

5 天前 - … Gemcitabine is the first-line treatment option for patients with locally … pancreatic
ductal adenocarcinoma (PDAC). However, the frequent adoption of resistance to gemcitabine by …

… -acting Erwinia chrysanthemi, Pegcrisantaspase, induces alternate amino acid biosynthetic pathways in a preclinical model of pancreatic ductal adenocarcinoma

D Bollino, K Hameed, A Bhat, A Zarrabi, A Casildo… - Cancer & …, 2024 - Springer

8 天前 - … of Eryaspase in combination with gemcitabine + nab paclitaxel or FOLFIRI (folinic
acid, fluorouracil, irinotecan) in advanced pancreatic cancer revealed that although patients …

3D imaging of immune cell reaction in pancreatic cancer organoids: the response to a nanovaccine therapy

N Ferreira - 2024 - ediss.uni-goettingen.de

10 天前 - … challenges in pancreatic ductal adenocarcinoma (PDAC), … evasive microenvironment
and resistance to conventional … This study reveals distinct responses to gemcitabine in …

[PDF] lsuhsc.edu

[PDF][PDF] … specific Anti-PD-L1/TGF-Antibody Synergizes with Chemotherapy as Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma: a Preclinical Experimental …

H Zhang, J Chen, J Bai, J Zhang, S Huang - digitalscholar.lsuhsc.edu

11 天前 - … Cadherin 11 promotes immunosuppression and extracellular matrix deposition to
support growth of pancreatic tumors and resistance to gemcitabine in mice. Gastroenterology …

[PDF] nature.com

N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance

MJ Ma, YH Shi, ZD Liu, YQ Zhu, GY Zhao, JY Ye, FX Li… - Oncogene, 2024 - nature.com

13 天前 - … Gemcitabine resistance is a major obstacle to the effectiveness of chemotherapy in
pancreatic ductal adenocarcinoma (PDAC… cancer cells to gemcitabine. Here, we constructed …

BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism

H Sun, H Li, Y Guan, Y Yuan, C Xu, D Fu, P Xie, J Li… - Science …, 2024 - science.org

18 天前 - … of drug resistance driven by pancreatic cancer stem cells. … resistance in pancreatic
ductal adenocarcinoma (PDAC) … signaling greatly improves the gemcitabine (GEM) efficacy …

[HTML][HTML] Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma

N Fraunhoffer, P Hammel, T Conroy, R Nicolle… - Annals of …, 2024 - Elsevier

19 天前 - … of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated
with adjuvant chemotherapy, commonly consisting of gemcitabine-… effective than gemcitabine-…

Gemcitabine-loaded chitosan nanoparticles enhanced apoptotic and ferroptotic response of gemcitabine treatment alone in the pancreatic cancer cells in vitro

D Aydemir, K Öztürk, FB Arslan, S Çalis… - Naunyn-Schmiedeberg's …, 2024 - Springer

20 天前 - … ductal adenocarcinoma (PDAC) patients, causing side effects and poor overall
survival. Eighty percent of patients often develop resistance … Pancreatic ductal adenocarcinoma (…

ROBO1 Drives Gemcitabine Resistance in Pancreatic Cancer

S Mader, I Rooman, ER Aznar, P Soubeyran, N Dusetti… - 2024 - researchportal.vub.be

21 天前 - … Pancreatic Ductal Adenocarcinoma (PDAC) has a dismal prognosis, owing to its
heterogeneity, high metastatic spread and resistance … PDAC response to gemcitabine and may …